PEG-uricase, a polyethylene glycol ("PEG") conjugate of recombinant porcine uricase (urate oxidase), which breaks down the uric acid deposits is being studied in Phase III clinical trials for the treatment...
- Mechanism
- Curator reviewed
PEG-uricase is a recombinant, PEGylated formulation of a modified porcine urate oxidase intended to dramatically lower the blood level of uric acid safely and continuously in patients who have not benefited from conventional therapeutic approaches. Urate oxidase is a hepatic enzyme present in almost all mammals – but not in humans – that lowers uric acid levels in the blood by converting uric acid into allantoin, a benign substance which is then easily excreted in the urine.
- Primary indication
- Investigated for use/treatment in hyperuricemia.Curator reviewed
- Also known as
- Polyethylene glycol-modified uricase
Resolves to
What you can answer from here — as of April 20, 2023
Which drugs share a target with PEG-uricase, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account